Abstract:The advancement of cancer‐fighting drugs has never been a simple linear process. Those drug design professionals begin to find inspiration from the nature after failing to find the ideal products by creative drug design and high‐throughput screening. To obtain new molecules for inhibiting tubulin, podophyllotoxin was adopted as the leading compound and 1,3,4‐oxadiazole was brought in to the C‐4 site of podophyllotoxin in this research. A series of seventeen podophyllotoxin‐derived esters have been achieved and then evaluated their antitumor activities against four different cancer cell lines: A549, MCF‐7, HepG2, and HeLa. Among all the compounds, compound 7c showed the best antiproliferating properties with IC50 = 2.54 ± 0.82 μm against MCF‐7 cancer cell line. It was obvious that the content of ROS grew significantly in MCF‐7 in a way depending on the dosage. The time‐ and dose‐dependent cell cycle assays revealed that compound 7c could apparently block cell cycle in the phase of G2/M along with the upregulation of cyclin A2 and CDK2 protein. According to further studies, confocal microscopy experiment has certified that compound 7c could restrain cancer from growing by blocking the polymerization of microtubule. Meanwhile, compound 7c could be ideally integrated with the colchicine site of tubulin. In future, it would be feasible to selectively design tubulin inhibitors with the help of 3D‐QSAR. This means that it is hopeful to develop compound 7c as a potential agent against cancer due to its biological characteristics.

Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

Advances of podophyllotoxin and its derivatives: Patterns and mechanisms

Podophyllotoxin: History, Recent Advances and Future Prospects

Synthesis And Evaluation Of New Podophyllotoxin Derivatives With In Vitro Anticancer Activity

Podophyllotoxin: Current approaches to its biotechnological production and future challenges

Insight Into the Molecular Mechanism of Podophyllotoxin Derivatives as Anticancer Drugs

Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.

Podophyllotoxin: Recent Advances in the Development of Hybridization Strategies to Enhance Its Antitumoral Profile

Podophyllotoxin, a medicinal agent of plant origin: past, present and future

Design, Synthesis, and Biological Evaluation of Novel Biotinylated Podophyllotoxin Derivatives as Potential Antitumor Agents

Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents

A recent antitumor story of podophyllotoxin derivatives targeting tubulin: an update (2017-2022)

Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010–2020)

Podophyllotoxin Derivatives: Current Synthetic Approaches for New Anticancer Agents

Syntheses and structure-activity relationship of podophyllotoxin derivatives as potential anticancer drugs

Design, Synthesis, Biological Evaluation, and 3D-QSAR Analysis of Podophyllotoxin-Dioxazole Combination As Tubulin Targeting Anticancer Agents.

Novel linear and step-gradient counter-current chromatography for bio-guided isolation and purification of cytotoxic podophyllotoxins from Dysosma versipellis (Hance).

Design, Synthesis and Biological Evaluation of Novel Podophyllotoxin Derivatives Bearing 4Β-Disulfide/trisulfide Bond As Cytotoxic Agents